期刊
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
卷 97, 期 7, 页码 1110-1114出版社
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2011.057372
关键词
CD20; multiple myeloma; cell lines; stem cell; phenotype
类别
资金
- Cooperative Research Thematic Network (RTICs) [RD06/0020/0006]
- Junta de Castilla y Leon. Consejena de Sanidad [GRS 391/B/09]
- Ministerio de Ciencia e Innovacion [PS09/01897]
- Fundacion Memoria D. Samuel Solorzano Barruso [FS/2-2010]
Although new therapies have doubled the survival of multiple myeloma patients, this remains an incurable disease. It has been postulated that the so-called myeloma cancer stem cells would be responsible for tumor initiation and relapse but their unequivocal identification remains unclear. Here, we investigated in a panel of myeloma cell lines the presence of CD20(+) cells harboring a stem-cell phenotype. Thus, only a small population of CD20(dim+) cells (0.3%) in the RPMI-8226 cell line was found. CD20(dim+) RPMI-8226 cells expressed the plasma cell markers CD38 and CD138 and were CD19(-) CD27(-). Additionally, CD20(dim+) RPMI-8226 cells did not exhibit stem-cell markers as shown by gene expression profiling and the aldehyde dehydrogenase assay. Furthermore, we demonstrated that CD20(dim+) RPMI-8226 cells are not essential for CB17-SCID mice engraftment and show lower self-renewal potential than the CD20(-) RPMI-8226 cells. These results do not support CD20 expression for the identification of myeloma cancer stem cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据